Inhibitor‐induced dimerization mediates lufotrelvir resistance in mutants of SARS ‐ CoV ‐2 3C‐like protease
Protein Science · 2025-09 · 34 (9)
DOI: 10.1002/pro.70275 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Science, online erschienen am 25.08.2025. Verfasst von Guanyu Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Coronavirus 3C Proteases, SARS-CoV-2, Drug Resistance, Viral, Antiviral Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada, CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
The emergence of SARS‐CoV‐2 and other lethal coronaviruses has prompted extensive research into targeted antiviral treatments, particularly focusing on the viral 3C‐like protease (3CL pro ) due to its essential role for viral replication. However, the rise of drug resistance mutations poses threats to public health and underscores the need to predict resistance mutations and understand the mechanism of how these mutations confer resistance. The binding of inhibitor to 3CL pro drives it from the monomeric to the active dimeric form, which can counterintuitively lead to enzyme activation rather than inhibition. Furthermore, we find this allosteric coupling between binding and dimerization is sensitive to mutation, leading to a new mechanism for drug resistance. Understanding the relationship between inhibitor binding and dimerization is important for resistant strain surveillance and development of robust antivirals. Herein, we present a systematic study of drug resistance mediated by inhibitor‐induced dimerization of 3CL pro .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, McGill University, Montreal, Quebec, Canada.
- Departamento de Ciencias Biomédicas, Facultad de Medicina, Universidad Católica del Norte, Coquimbo, Chile.
- Programa de Doctorado en Ciencias Biomédicas, Facultad de Medicina, Universidad Católica del Norte, Coquimbo, Chile.
- Centro de Modelación Ambiental y Dinámica de Sistemas (CEMADIS), Facultad de Ingeniería y Negocios, Universidad de Las Américas, Santiago, Chile.
- Facultad de Odontología, Universidad Andres Bello, Santiago, Chile.
- Facultad de Medicina, Universidad Diego Portales, Santiago, Chile.
ORCID-Profile: Guanyu Wang, Osvaldo Yañez, Manuel I Osorio, Sibei Qin, José Manuel Pérez-Donoso, Christopher J Thibodeaux, Nicolas Moitessier, Anthony K Mittermaier
Förderung
- Natural Sciences and Engineering Research Council of Canada
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Wang, G., Venegas, F., Rueda, A., Yañez, O., Osorio, M. I., Qin, S., Pérez-Donoso, J. M., Thibodeaux, C. J., Moitessier, N., & Mittermaier, A. K. (2025). Inhibitor‐induced dimerization mediates lufotrelvir resistance in mutants of SARS ‐ CoV ‐2 3C‐like protease. Protein Science, 34(9). https://doi.org/10.1002/pro.70275
Vancouver
Wang G, Venegas F, Rueda A, Yañez O, Osorio MI, Qin S, et al. Inhibitor‐induced dimerization mediates lufotrelvir resistance in mutants of SARS ‐ CoV ‐2 3C‐like protease. Protein Science. 2025;34(9). doi:10.1002/pro.70275
BibTeX
@article{Wang2025,
author = {Wang, Guanyu and Venegas, Felipe and Rueda, Andres and Yañez, Osvaldo and Osorio, Manuel I and Qin, Sibei and Pérez-Donoso, José Manuel and Thibodeaux, Christopher J and Moitessier, Nicolas and Mittermaier, Anthony K},
title = {Inhibitor‐induced dimerization mediates lufotrelvir resistance in mutants of SARS ‐ CoV ‐2 3C‐like protease},
journal = {Protein Science},
year = {2025},
volume = {34},
number = {9},
doi = {10.1002/pro.70275}
}
EUVIMED